Final result of the voluntary offer for Weifa ASA
(Thomson Reuters ONE) -
Following final registration of acceptances, the final acceptance level in Karo
Pharma AB's ("Karo Pharma") voluntary offer ("Voluntary Offer") to acquire all
shares in Weifa ASA ("Weifa") is 35,463,139 shares representing 97.23% of the
total shares in Weifa on a fully diluted basis.
It is expected that the settlement of the Voluntary Offer will take place on or
about 6 October 2017 and that the cash consideration will be available on the
accepting Weifa shareholders' registered bank accounts in the VPS on or about 9
October 2017.
Upon settlement of the Voluntary Offer, Karo Pharma will hold more than 90% of
all the shares in Weifa. Karo Pharma intends to initiate a compulsory
acquisition of the remaining outstanding shares of Weifa at a price equal to the
offer price of NOK 35 per share, and to propose that Weifa applies for a
delisting of its shares from Oslo Børs.
For further information, please contact:
Peter Blom, CEO of Karo Pharma, +46 070-655 56 98 or peter.blom(at)karopharma.se
Simen Nyberg-Hansen, CFO of Weifa: +47 9820 6355, or simen.nyberg-
hansen(at)weifa.no
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Weifa ASA via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 05.10.2017 - 17:00 Uhr
Sprache: Deutsch
News-ID 562660
Anzahl Zeichen: 1675
contact information:
Town:
Oslo
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 237 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Final result of the voluntary offer for Weifa ASA"
steht unter der journalistisch-redaktionellen Verantwortung von
Weifa ASA (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
